Lineage Cell posts break-even EPS and 130% revenue growth in Q4
Lineage Cell achieved break-even adjusted EPS in Q4 versus the expected $0.07 loss, reversing last year’s $0.01 loss. Revenue jumped to $6.61 million, 130% above the $2.87 million a year ago and 188% above consensus estimates.
1. Break-Even EPS Surprise
Lineage Cell reported adjusted EPS of $0.00 for Q4, beating the consensus loss estimate of $0.07 and improving from a $0.01 loss in the year-ago period. This marks a 100% earnings surprise and represents the second positive deviation from estimates in the past four quarters.
2. Record Revenue Growth and Outlook
Revenue rose to $6.61 million, up 130% year-over-year and 188% above analyst forecasts, driven by robust sales in core cell therapy products. Current consensus calls for a Q1 loss of $0.03 on $1.92 million in revenues and a full-year EPS loss of $0.06 on $18.82 million, setting the stage for investor focus on upcoming guidance.